The Pharmaceutical Division is one of Ariti’s fastest growing sectors
Ariti has been active in the pharmaceutical area since the end of 2008.
The first pharmaceutical product (LETRAFEM/ letrozole), was authorised back in June 2011 and quickly gained recognition in Oncology for the treatment of breast cancer.
In 2019, a new business unit was created, consisting of executives specialized in orphan drugs, aiming to offer therapeutic solutions to patients in Greece and Cyprus, diagnosed with a rare disease.
The scientifically trained personnel of the pharmaceutical division interacts with healthcare professionals and participates continuously in the most important domestic or international medical events. Α well-organized Regulatory Affairs and Pharmacovigilance department constitutes another crucial part of this division, with personnel of great expertise.
Finally, with the constant research of the global market and the longstanding cooperation with reliable companies of the pharmaceutical industry, Ariti deploys an ambitious development plan for the years to come.
TREATMENT CATEGORIES
| Letrafem® | Letrozole | Antineoplastic Agent,Non Steroid Aromatase inhibitor | ΦΟΧ |
| Rectoxal® | Oxaliplatin | Antineoplastic Agent, Platinum Compound | ΦΟΧ |
| Irican® | Irinotecan hydrochloride trihydrate | Chemotherapeutic agent Topoisomerase inhibitor | ΦΟΧ |
| Topocan® | Topotecan hydrochloride | Chemotherapeutic agent Topoisomerase inhibitor | ΦΟΧ |
| Gemlag® | Gemcitabine Hydrochloride | Chemotherapeutic agent, nucleoside analog | ΦΟΧ |
| Capibine® | Capecitabine | Antineoplastic agent – Pyrimidine analogue | ΦΟΧ |
| Sunitinib Ariti | Sunitinib Malate | Antineoplastic and immunomodulatory agents. Antineoplastic drugs. | ΦΟΧ |
| Abiraterone Ariti 500mg | Abiraterone | Hormone (endocrine) therapy, Other hormone antagonists and related agents | ΦΟΧ |
| Alfuzin® | Alfuzosin Hydrochloride | Medications used in disorders of the urinary system. Drugs used in benign prostatic hypertrophy | ΦΟΧ |
| Lutrak® | Bicalutamide | Antineoplastic agent – Antiandrogen | ΦΟΧ |
| Solicin® | Solifenacin succinate | Gastrointestinal antispasmodics | ΦΟΧ |
| Tamsulosin Ariti | Tamsulosin Hydrochloride | Drugs used in benign prostatic hypertrophy, Alpha-adrenoreceptor antagonist | ΦΟΧ |
| Tadalafil Ariti | Tadalafil | Drugs used in the treatment of erectile dysfunction, Phosphodiesterase type 5 inhibitor | ΦΟΧ |
| Solifenacin + Tamsulosin Ariti | Solifenacin Succinate + Tamsulosin Hydrochloride | Medicines for diseases of the urinary system. Drugs used in benign prostatic hypertrophy. | ΦΟΧ |
| Quetiapine Ariti | Quetiapine Fumarate | Drugs for Central Nervous System. Antipsychotic drugs. Diazepines, oxazepines and thiazepines. | ΦΟΧ |
| Peziled® | Donepezil Hydrochloride | Treatment of Alzheimer’s disease, Acetylcholinesterase inhibitor | ΦΟΧ |
| Escitalopram Ariti | Escitalopram Oxalate | Antidepressants, Selective serotonin reuptake inhibitor | ΦΟΧ |
| Memantine Ariti | Memantine Hydrochloride | Anti-dementia drugs, NMDA receptor antagonist | ΦΟΧ |
| Prazarit® | Aripiprazole | Antipsychotic | ΦΟΧ |
| Rasagiline Ariti | Rasagiline tartrate | Τreatment of Parkinson’s disease, Selective monoamine oxidase inhibitor | ΦΟΧ |
| Magnesium Sulfate Ariti | Magnesium Sulfate Heptahydrate | Digestive tract and metabolism. Additions of metal elements. | ΦΟΧ |
| Adrenaline Ariti | Epinephrine | Adrenergic agents for hospital use | ΦΟΧ |
| Atropine Ariti | Atropine Sulfate | Alkaloids of euthalia, tertiary amines, muscarinic antagonist | ΦΟΧ |
| CALCIUM GLUCONATE/ARITI | Calcium Gluconate | Digestive tract and metabolism. Mineral supplements | ΦΟΧ |
| Colistimethate Sodium Ariti | Colistimethate Sodium | Anti-infective drugs for systemic administration. Antibiotics for systemic administration. | ΦΟΧ |
| Dexmedetomidine Ariti | Dexmedetomidine Hydrochloride | Psychotropic and Sedatives. | ΦΟΧ |
| Sugammadex Ariti | Sugammadex Sodium | Other medicines | ΦΟΧ |
| Lenalidomide Ariti | Lenalidomide | Other immunosuppressants | ΦΟΧ |
| Fenedim®Gel | Dimetindene maleate | Antihistamines for topical use, Drugs of the alkylamine group | ΦΟΧ |
On Rare Disease Day 2019, 28th of February, Ariti launched a new business unit within the pharmaceutical division, working exclusively on rare disorders. The newly formed team is composed of experienced personnel in the field of orphan medicinal products both in local and international markets. Our main goal would be to offer therapeutic solutions to patients suffering from rare diseases in Greece and Cyprus, through collaborations with other pharmaceutical companies.
- Access to therapy
We engage in different steps during the lifecycle of a product, guiding our partners on early access programs (EAPs), named patient programs (NPPs) and Pricing & Reimbursement process. - Product handling
We ensure proper storage and transport conditions for the pharmaceutical products through the country - Pharmacovigilance
The Pharmacovigilance department provides comprehensive support in managing the safety profile of pharmaceutical products by applying special procedures based on the current legislation. - Marketing and Sales
Our goal is to achieve ideal market penetration for a specific pharmaceutical product. Our priority is to apply strategies to increase disease awareness, engage HCPs into active patient identification initiatives and expose stakeholders to the added value of a given pharmaceutical product. - Market and Disease Analysis
We provide analysis on disease prevalence, centers of excellence, diagnostic centers, patient organizations as well as HCPs and KOL networks dealing with a specific disorder. Our report provides information on current disease management guidelines as well as competitive landscape analysis.
NTM LUNG DISEASE
For scientific information and pharmacovigilance please call +30 2108002650 οr +30 6981672031, or send us an e-mail at: pharmacovigilance@ariti.gr